Evidence map›Paper›PMID 40161305›Full record

ArticleEuropean heart journal open2025

Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: results from the noninterventional Global ETNA-AF programme.

Doralisa Morrone, Leon Dinshaw, José Antonio Gordillo de Souza, Cathy Chen, Paulus Kirchhof, Yukihiro Koretsune, Ladislav Pecen, Chun-Chieh Wang, Takeshi Yamashita, Martin Unverdorben and 1 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02944019 completednot on this map

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

TypeobservationalSponsorDaiichi SankyoRan2015 to 2022Enrolled13,980ConditionsAtrial FibrillationArmsEdoxaban
NCT02951039 completednot on this map

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF)

TypeobservationalSponsorDaiichi SankyoRan2017 to 2020Enrolled3,008ConditionsAtrial FibrillationArmsEdoxaban
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Doralisa MorroneDepartment of Surgery, Medical, Molecular, and Critical Area Pathology, University of Pisa, Via Paradisa 2, Pisa 50124, Italy.ORCID https://orcid.org/0000-0002-9667-6931
Leon DinshawUniversitäres Herzzentrum Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany.ORCID https://orcid.org/0000-0002-1473-5716
José Antonio Gordillo de SouzaDaiichi Sankyo Europe GmbH, Zielstattstraße 48, Munich 81379, Germany.
Cathy ChenDaiichi Sankyo, Inc., 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA.
Paulus KirchhofCenter for Cardiovascular Research, University of Birmingham and SWBH and UHB NHS Trusts, Birmingham B15 2TT, UK.ORCID https://orcid.org/0000-0002-1881-0197
Yukihiro KoretsuneNational Hospital Organization Osaka National Hospital, 2 Chome-1-14 Hoenzaka, Chuo Ward, Osaka 540-0006, Japan.ORCID https://orcid.org/0000-0003-1650-8362
Ladislav PecenInstitute of Computer Science of the Academy of Sciences of the Czech Republic, Pod Vodárenskou věží 2, Prague 18200, Czech Republic.ORCID https://orcid.org/0000-0001-9827-3178
Chun-Chieh WangDivision of Cardiology, Department of Internal Medicine, Chang Gung University and Chang Gung Memorial Hospital, No. 5, Fuxing St, Guishan District, Taoyuan 333, Taiwan.
Takeshi YamashitaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-ku, Tokyo 106-0031, Japan.ORCID https://orcid.org/0000-0002-2544-8464
Martin UnverdorbenDaiichi Sankyo, Inc., 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA.ORCID https://orcid.org/0000-0002-3601-8187
Raffaele De CaterinaChair of Cardiology, University of Pisa, and Cardiology 1 Division, Pisa University Hospital, Via Paradisa 2, Pisa 56125, Italy.ORCID https://orcid.org/0000-0003-1637-574X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: The 2020 European Society of Cardiology (ESC)-atrial fibrillation (AF) guidelines recommend a risk-based approach to oral anticoagulation (OAC) therapy in patients with AF; however, it is unknown if current practice aligns with these recommendations. This study assessed the associated effectiveness and safety of edoxaban in patients with AF according to the 2020 ESC-AF guidelines and the approved label in routine clinical care. Methods and results: The Global ETNA-AF programme is a large prospective, noninterventional programme evaluating safety and effectiveness of edoxaban. Baseline characteristics and 2-year clinical event data were analysed in subgroups, defined by ESC-AF guidelines indication of OAC therapy according to CHA Conclusion: This study demonstrated that edoxaban use in patients with AF largely aligns with 2020 ESC-AF guidelines, while maintaining low clinical event rates. Registration: Europe (NCT02944019), Japan (UMIN000017011), and Korea/Taiwan (NCT02951039).

Indexed as

Atrial fibrillationEdoxabanOral anticoagulation

Identifiers

PMID40161305
PMCPMC11951963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.